Recent Updates
Recently added Catalysts

recombinant tissue plasminogen activator

Phase 3

Pulmonary Embolism | Small molecule | Other |Boston Scientific Corporation|Last Updated: Jul 19, 2021

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment150
FDA Designations
No designations recorded
Clinical trial landscape

recombinant tissue plasminogen activator · 2 trials · 10 indications

Phase 3 2
NCT00790335Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed ThrombolysisDeep Vein Thrombosis
COMPLETED692 Analytics
NCT01513759Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis TherapyPulmonary Embolism
COMPLETED150 Analytics
PHASE3COMPLETED
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein ThrombosisUnlock trial analytics
PHASE3COMPLETED
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
Pulmonary EmbolismUnlock trial analytics
Study Endpoints
Primary Endpoints
Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale)
Between 6 and 24 months after randomization

Patients who experienced one of the following occurrences in the index leg between the 6 month and 24 month post-randomization follow-up visits, inclusive: 1) Villalta score of 5 or greater; 2) leg ulcer; or 3) late endovascular procedure performed to treat severe venous disease. The Villalta scale ranges from 0-33 points, with higher scores being worse.

Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio Within 48 +/- 6 Hours of Initiation of Therapy
Baseline, within 48 +/- 6 hours of initiation of therapy

Change from baseline in RV diameter/LV diameter ratio was determined by contrast-enhanced chest computed tomography (CT) within 48 +/- 6 hours after initiating ultrasound-accelerated catheter-directed fibrinolysis.

Number of Participants With Major Bleeding
From start of study drug infusion up to 72 hours

Bleeding adverse events were graded (severe or life-threatening, moderate or mild bleeding) according to the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) classification. The participant incidence of major bleeding events was defined as GUSTO moderate and severe events occurring within 72 hours after starting the ultrasound-accelerated catheter-directed fibrinolysis procedure. Mild: Does not meet criteria for moderate or severe; Moderate: Requires transfusion - No hemodynamic compromise; and Severe: Bleeding causes hemodynamic compromise and required intervention or intracranial hemorrhage. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Secondary Endpoints
Major Non-post-thrombotic Syndrome Treatment Failure
Through 24 months
Any Treatment Failure
Through 24 months
Moderate-to-severe Post-thrombotic Syndrome
Between 6 and 24 months after randomization
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
A-InterventionEXPERIMENTALPCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
B-ControlNO_INTERVENTIONInitial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
EkoSonic® Endovascular SystemEXPERIMENTALParticipants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
Interventions
NameTypeDescription
Recombinant tissue plasminogen activator (rt-PA)DRUGPharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
recombinant tissue plasminogen activatorDRUGParticipants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
EKOS EkoSonic Endovascular SystemDEVICE24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
Unlock Study Design Details
Eligibility Criteria
Age Range16 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites56

Inclusion Criteria: * Symptomatic proximal DVT involving the iliac, common femoral, and/or femoral vein. Exclusion Criteria: * Age less than 16 years or greater than 75 years. * Symptom duration \> 14 days for the DVT episode in the index leg (i.e., non-acute DVT). * In the index leg: established...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Pulmonary Embolism 6 trials